Heron Therapeutics reported its Q1 2026 results highlighting increased operating expense efficiency, ongoing liquidity management, and solid patent litigation verdicts preserving exclusivity for key products. The company’s proprietary Biochronomer Technology underpins a differentiated portfolio including ZYNRELEF and CINVANTI, supported by favorable FDA designations and reimbursement pathways. While competition from generics and reliance on third-party manufacturers remain risks, Heron’s commercial focus and recent developments position it for growth in acute pain management and oncology supportive care.